Eiger BioPharmaceuticals, Inc. (EIGR)
Stock Price:
$11.49 USD
0.21 (1.86%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $11.45 -0.04 (-0.35%) Aug 13, 5:48 PM
Key Info
| Market Cap |
336.00M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-66.10M |
| Shares Out |
25.06M |
| EPS (ttm) |
-2.69 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 13, 2020 |
| Last Price |
$11.49 |
| Previous Close |
$11.28 |
| Change ($) |
0.21 |
| Change (%) |
1.86% |
| Day's Open |
11.48 |
| Day's Range |
11.20 - 11.87 |
| Day's Volume |
701,071 |
| 52-Week Range |
4.55 - 15.82 |
More Stats
| Market Cap |
336.00M |
| Enterprise Value |
277.58M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
25.06M |
| Float |
25.03M |
| EPS (basic) |
-2.66 |
| EPS (diluted) |
-2.69 |
| FCF / Share |
-2.50 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
689,974 |
| Short Ratio |
1.88 |
| Short % of Float |
3.08% |
| Beta |
1.33 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.64 |
| Revenue |
n/a |
| Operating Income |
-64.17M |
| Net Income |
-66.10M |
| Free Cash Flow |
-63.68M |
| Net Cash |
58.43M |
| Net Cash / Share |
2.00 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-33.45% |
| ROE |
-90.20% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$34.67*
(201.74% upside)
Low
23.0
Current: $11.49
High
56.0
Target: 34.67
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Operating Income | -68.90 | -51.05 | -41.52 | -46.12 | -12.97 | -1.52 | -19.96 | -15.95 | -6.03 |
| Net Income | -70.25 | -52.39 | -42.45 | -47.09 | -13.32 | -1.52 | -20.00 | -15.72 | -6.99 |
| Shares Outstanding | 22.79 | 13.63 | 8.73 | 6.01 | 0.21 | 0.19 | 0.06 | 0.05 | - |
| Earnings Per Share | -3.08 | -3.84 | -4.86 | -7.84 | -62.19 | -7.82 | -406.41 | -295.95 | -40,924.44 |
| Operating Cash Flow | -63.61 | -42.67 | -38.37 | -37.97 | -9.13 | -1.28 | -16.20 | -14.64 | -5.61 |
| Capital Expenditures | -0.48 | -0.14 | -0.04 | -0.06 | -0.05 | - | -0.09 | -0.05 | 0.04 |
| Free Cash Flow | -64.09 | -42.81 | -38.42 | -38.03 | -9.18 | -1.28 | -16.28 | -14.69 | -5.58 |
| Cash & Equivalents | 94.99 | 100 | 41.78 | 59.94 | 4.78 | 84.95 | 18.37 | 32.65 | 0.00 |
| Total Debt | 32.24 | 25.62 | 15.09 | 14.73 | 5.44 | - | 1.04 | - | - |
| Net Cash / Debt | 62.75 | 74.73 | 26.69 | 45.21 | -0.67 | 84.95 | 17.33 | 32.65 | 0.00 |
| Assets | 105 | 102 | 42.88 | 60.74 | 5.58 | 89.11 | 21.15 | 35.93 | - |
| Liabilities | 48.66 | 35.86 | 20.36 | 20.02 | 10.73 | 17.01 | 72.15 | 64.35 | - |
| Book Value | 56.48 | 66.59 | 22.52 | 40.72 | -5.15 | 72.10 | -50.99 | -28.42 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Eiger BioPharmaceuticals, Inc. |
| Country |
United States |
| Employees |
28 |
| CEO |
David A. Cory |
Stock Information
| Ticker Symbol |
EIGR |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: EIGR |
Description
Eiger BioPharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection. The company's product candidate also include Lambda, which targets type III interferon receptors that is in Phase 2 clinical trial; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide that has completed phase 2 clinical trial to treat post-bariatric hypoglycemia, as well as in phase 2 clinical trial for the treatment of congenital hyperinsulinism. The company is headquartered in Palo Alto, California.